ASCO Annual Meeting: Colorectal Cancer | Conference

Marwan G. Fakih, MD, Discusses Regorafenib Plus Nivolumab in CRC and Multidisciplinary Care
July 09, 2021

CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.

Consistent Activity of Trastuzumab Deruxtecan Reported for HER2+ mCRC
June 08, 2021

In line with responses seen at the primary analysis, final results of a phase 2 trial support activity of trastuzumab deruxtecan in HER2-positive metastatic CRC.

Maintenance Therapy Panitumumab Plus 5-FU/Leucovorin Improves Survival in RAS Wild-Type Metastatic CRC
June 08, 2021

Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC.

Preferred Treatment of RAS Wild-Type, BRAF V600E Mutant mCRC Favors Bevacizumab Over Cetuximab
June 07, 2021

Certain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.

Patients With Advanced CRC May Experience Survival Benefit With Lenvatinib Plus Pembrolizumab Combo
June 04, 2021

Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.

Liquid Biopsy to Inform Targeted Tx of Colorectal Cancer
June 21, 2018

In this video, Dr. Heinz-Josef Lenz outlines the many advantages that development of liquid biopsy is affording cancer patients.

Adjuvant FOLFOX Improved DFS in yp Stage III Rectal Cancer
June 06, 2018

In the ADORE trial, adjuvant FOLFOX in postoperative yp stage III rectal cancer significantly improved disease-free survival.

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
June 06, 2018

A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.

No OS Benefit From HIPEC in Colorectal Cancer
June 04, 2018

Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery.

mCRC Chemo Cost More in US Than in Canada, but Yielded No Better Survival
June 02, 2018

Despite paying nearly double per month for first-line treatment in the US, patients with mCRC have survival outcomes similar to their Canadian counterparts.